FDA Issues Warning Letter to Amazon for Unapproved Drug Products
FDA issued a warning letter to Amazon.com, Inc. after purchasing and reviewing products sold through Amazon’s website and fulfilled through Amazon’s logistics network. The products identified were “Vajraang Phimosis Mini Combo,” “Penile Heal Cream,” and “Beilloso Balanitis Relief Cream.”
FDA determined the products were unapproved new drugs because their labeling included claims related to phimosis, paraphimosis, and balanitis. FDA noted that these claims indicated the products were intended for diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.
The letter is particularly significant because FDA emphasized that the products were introduced or delivered for introduction into interstate commerce through Amazon’s Fulfillment by Amazon service. FDA directed Amazon to respond within 15 business days with corrective actions and preventive measures.
MDP Perspective
This warning letter should get the attention of online marketplaces, fulfillment providers, and third-party sellers.
FDA is not only looking at product manufacturers. It is also scrutinizing distribution channels when unapproved drug products reach U.S. consumers through major online platforms.
The Amazon letter reinforces that e-commerce companies need stronger controls over health-related claims, product listings, fulfillment pathways, and third-party seller compliance. Marketplace scale does not eliminate regulatory responsibility.
Links
Warning letter to Leading Edge Health, Inc.
Warning Letter to Wild Arabic Herbs
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...
